Ozempic Constipation: Why GLP-1 Drugs Slow Your Bowels

Ozempic constipation is a direct, expected effect of how GLP-1 drugs work: they slow gastric emptying and dampen intestinal motility, so food sits longer at every step from stomach to colon. In the pivotal STEP 1 trial of semaglutide 2.4 mg (the active ingredient in Ozempic and Wegovy), gastrointestinal events affected 74.2% of participants on the drug versus 47.9% on placebo, with constipation among the top four most-reported issues (Wilding et al., NEJM 2021). Most cases are mild, dose-related, and improve as the body adapts — but a small subset cross into gastroparesis, ileus, or bowel obstruction, and those are the patterns worth knowing before you reach for another laxative.

Key takeaways

• Constipation on Ozempic, Wegovy, and Mounjaro is mechanism-driven, not random — these drugs slow gastric emptying by design, which is also why they curb appetite (Diabetes, ADA).
• In the SURMOUNT-1 tirzepatide trial, constipation hit 11–17% of participants depending on dose, with diarrhea in 17–23% (Jastreboff et al., NEJM 2022).
• Median duration of constipation in the STEP semaglutide trials was 47 days versus 35 days for placebo, with prevalence plateauing around week 10 (Wharton et al., 2022).
• A 2023 JAMA cohort study found GLP-1 users had a 3.67-fold higher risk of gastroparesis and a 4.22-fold higher risk of bowel obstruction versus bupropion-naltrexone for weight loss (Sodhi et al., JAMA 2023).
• Red flags — persistent vomiting, severe abdominal pain, abdominal distension, no stool or gas for >48 hours — mean stop the drug and get evaluated for ileus or obstruction, not reach for MiraLAX.

How GLP-1 drugs slow your bowels

Glucagon-like peptide-1 (GLP-1) is a gut hormone normally released after a meal. Drugs like semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and the GLP-1 / GIP dual agonist tirzepatide (Mounjaro, Zepbound) mimic that hormone at much higher and longer-lasting doses. The downstream effects are exactly the ones that drive weight loss — and exactly the ones that change how stool moves.

The motility effects show up in three places:

• Stomach: GLP-1 receptor activation slows gastric emptying. Food stays in the stomach longer, which is why many users feel full on smaller portions and why nausea is the most common side effect (Diabetes, ADA).
• Small intestine: native GLP-1 inhibits the migrating motor complex (the housekeeping wave that sweeps the gut between meals) and reduces the number and amplitude of duodenal pressure waves.
• Colon: with slower upstream transit, less water and fewer bulk-formers reach the colon on the same schedule. Stool sits longer, dehydrates more, and ends up harder.

The effect is neurally mediated — GLP-1 receptors sit on the enteric and vagal nerves that control gut motility — and partially subject to tachyphylaxis, meaning the gastric-emptying effect can blunt over weeks of continuous use. That blunting is why Ozempic constipation often eases after the dose-escalation phase, but it’s not guaranteed and not uniform across users. For a primer on normal transit, see our piece on how long food takes to digest.

How common is Ozempic constipation?

Trial data is the cleanest answer, because real-world reporting is biased toward people who had a bad time. Here are the numbers from the major weight-loss trials.

STEP 1 — semaglutide 2.4 mg (Wegovy dose), 68 weeks

Gastrointestinal disorders — typically nausea, diarrhea, vomiting, and constipation — occurred in 74.2% of participants on semaglutide versus 47.9% on placebo (Wilding et al., NEJM 2021). The events were predominantly mild to moderate and concentrated in the dose-escalation phase.

STEP 5 — semaglutide over 2 years

Over 104 weeks, 82.2% of semaglutide-treated participants reported a GI adverse event compared with 53.9% on placebo (STEP 5, Nature Medicine 2022). The longer follow-up confirms that GI events don’t all resolve at the maintenance dose — they just become less common after the ramp-up.

Pooled STEP analysis — duration and time course

A pooled analysis of STEP 1, 2, 3, and 8 examined how long these GI events actually last. Median constipation duration was 47 days on semaglutide versus 35 days on placebo, and prevalence plateaued at roughly week 10 (Wharton et al., 2022). Across the program, 99.5% of GI events were non-serious and 98.1% mild or moderate.

SURMOUNT-1 — tirzepatide (Mounjaro / Zepbound)

In the 72-week SURMOUNT-1 trial, nausea occurred in 24–33% of tirzepatide users, diarrhea in 17–23%, constipation in 11–17%, and vomiting in 6–13%, depending on dose (Jastreboff et al., NEJM 2022). Tirzepatide tilts slightly more toward diarrhea than pure GLP-1 agonists, likely a consequence of dual GIP/GLP-1 action.

The pattern is consistent: about 1 in 7 to 1 in 5 users will get clinically meaningful constipation, mostly during the first several weeks of each dose increase, mostly resolving within weeks.

Why some people get diarrhea instead

The same drug producing both constipation and diarrhea seems contradictory until you separate the mechanisms. Diarrhea on GLP-1 drugs typically traces to one of three things:

• Bile acid malabsorption — slowed gastric emptying changes how bile acids are timed and absorbed; excess bile reaching the colon triggers secretory diarrhea.
• Diet shift — many users dramatically change what they eat (more lean protein, more vegetables, sometimes more sugar alcohols in “GLP-1-friendly” snacks). Sugar alcohols, FODMAPs, and unfamiliar fiber loads cause osmotic and fermentation-driven loose stools. Our low-FODMAP diet guide covers the food-trigger side of this.
• Microbiome shifts — early data suggests GLP-1 drugs alter gut microbial composition, though the clinical implications are still being worked out.

If your stool is consistently mushy or watery (Bristol Type 6–7 — see the full chart in our Bristol Stool Scale guide) rather than hard and infrequent, the management playbook is closer to the one in diarrhea: causes and when to worry than the one below.

How to manage GLP-1 constipation

The boring fundamentals matter more than any single fix.

1. Slow the dose escalation

Most GI events cluster during dose increases. If you’re tolerating 0.5 mg of semaglutide poorly, ask about staying there longer rather than pushing to 1.0 mg on schedule. Many clinicians extend the ramp-up by 4–8 weeks for patients with significant constipation, and the labels build in flexibility for this.

2. Hydrate, then add fiber gradually

The Academy of Nutrition and Dietetics targets are 25 g/day for women and 38 g/day for men of total fiber. Most US adults eat closer to 15 g, and on Ozempic — eating less overall — the gap usually widens. But the order matters: fiber without enough fluid bulks stool up without softening it, which makes Ozempic constipation worse. Pair every fiber bump with adequate water, and ramp by 2–3 g/day every few days, not all at once. See how hydration affects stool for the mechanism and fiber and stool consistency for which fibers do what.

3. Move

Walking 20–30 minutes most days speeds colonic transit independent of any drug. Our exercise and bowel movements deep dive covers the dose and which workouts move stool best.

4. Use PEG (MiraLAX) before stronger laxatives

The 2023 American Gastroenterological Association / American College of Gastroenterology joint guideline on chronic idiopathic constipation gave polyethylene glycol (PEG, sold as MiraLAX) a strong recommendation as the OTC of choice, with durable response over at least six months and mild side effects. Stimulant laxatives (senna, bisacodyl) are conditional recommendations — fine for shorter courses, not as daily crutches. We unpack the full ladder of remedies in constipation: what actually works.

Magnesium oxide is also conditionally recommended, but skip it if you have kidney disease, are over 65, or take other meds that affect electrolytes — clear it with the prescribing clinician first.

5. Don’t stack stool softeners

Docusate (Colace) didn’t make the cut in the 2023 guideline — evidence of efficacy is weak, and adding it to an already-effective PEG regimen is mostly placebo.

When it’s not just constipation: red flags

A small fraction of GLP-1 users develop more serious upper-GI complications. These are the patterns that mean stop self-managing and call the prescriber:

• Persistent nausea and vomiting for more than a few days, especially with retained food at meals you ate hours earlier — possible gastroparesis (stomach paralysis). The FDA Ozempic label states the drug is not recommended in patients with severe gastroparesis (FDA Ozempic label, 2025).
• No bowel movement and no gas for 48+ hours, with abdominal distension and pain — possible ileus (loss of intestinal contractions). The FDA added ileus to the Ozempic warning label in September 2023 after post-marketing reports.
• Severe, crampy abdominal pain with vomiting — possible bowel obstruction. The 2023 JAMA cohort study found GLP-1 users had a 4.22-fold higher risk of bowel obstruction versus bupropion-naltrexone (95% CI, 1.02–17.40), though the absolute risk remained low (Sodhi et al., JAMA 2023).
• Black, tarry stools or visible blood — see our black stool causes guide for the upper-GI bleeding picture; this is not something to assume the drug caused.
• Severe upper-abdominal pain radiating to the back — possible pancreatitis, which is in the GLP-1 label warnings as well.

These are uncommon but real. The 2023 JAMA analysis pegged the gastroparesis hazard ratio at 3.67 (95% CI, 1.15–11.90), again with low absolute event counts but a clear signal versus other weight-loss drugs.

FAQ

Does Ozempic always cause constipation? No. About 1 in 7 to 1 in 5 users will get clinically meaningful constipation, concentrated during dose increases. Most cases are mild, resolve in weeks, and respond to fluid, fiber, and PEG. A meaningful subset get diarrhea instead, and many users have neither.

How long does GLP-1 constipation last? In the pooled STEP semaglutide trials, median constipation duration was 47 days on the drug versus 35 days on placebo, with prevalence plateauing around week 10 (Wharton et al., 2022). Most users see things settle after the dose-escalation phase ends.

Can I take MiraLAX with Ozempic? Yes — PEG / MiraLAX is the OTC laxative with the strongest evidence base for chronic constipation per the 2023 AGA-ACG joint guideline, and there’s no specific interaction with GLP-1 drugs. Talk to your prescriber before chronic daily use, especially if you have kidney disease.

Is “Ozempic colon paralysis” a real thing? The clinical term is gastroparesis (stomach paralysis) or ileus (intestinal paralysis), and both have been reported in GLP-1 users post-marketing. The FDA added ileus to the Ozempic label in 2023. A 2023 JAMA cohort study found a 3.67-fold increased risk of gastroparesis with GLP-1 agonists for weight loss versus bupropion-naltrexone (Sodhi et al., JAMA 2023). Absolute risk is low, but the signal is real.

Does Mounjaro cause less constipation than Ozempic? Per the SURMOUNT-1 trial, tirzepatide caused constipation in 11–17% of users — slightly lower than semaglutide rates, but it caused more diarrhea (17–23%) (Jastreboff et al., NEJM 2022). The total GI burden is similar; the mix is different.

Should I stop the drug if I’m constipated? Not without talking to your prescriber. Most cases improve with hydration, fiber, movement, and PEG, plus a slower dose escalation. Stop and call urgently only for the red flags — persistent vomiting, severe abdominal pain, abdominal distension with no stool or gas for 48+ hours. If discontinuation is on the table for other reasons, our companion piece on what happens to your gut microbiome after stopping semaglutide covers the post-cessation biology and why fiber intake matters most in the weeks around coming off the drug.

The bottom line

Ozempic constipation is built into how GLP-1 drugs work. They slow stomach emptying and gut motility, which is why they suppress appetite and why stool gets harder and less frequent. Rates run roughly 11–24% across the trial program, mostly mild, mostly clustered around dose increases, mostly resolving after week 10 or so. The boring fixes — slower escalation, water, gradual fiber, walking, PEG — handle the majority of cases. What changes the conversation is duration plus severity: persistent vomiting, severe pain, distension with no stool or gas, or any of the classic GI red flags. Those are the cases where the drug needs to pause and a clinician needs to evaluate.

PoopCheck logs Bristol type, color, and frequency from a photo, which is exactly the data your prescriber will ask for when they’re trying to decide whether your stool drift is normal Ozempic adaptation or something that needs a workup. Tracking from week one of a new dose makes the difference between “I think I’m constipated” and “I’ve been Bristol Type 1–2 for three weeks since the dose increase, and frequency dropped from daily to every four days.”

Sources

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding JPH et al., N Engl J Med 2021;384(11):989–1002 (STEP 1 trial).
2. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial — Garvey WT et al., Nat Med 2022;28:2083–91.
3. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity — Wharton S et al., Diabetes Obes Metab 2022;24(8):1553–1562.
4. Tirzepatide Once Weekly for the Treatment of Obesity — Jastreboff AM et al., N Engl J Med 2022;387:205–216 (SURMOUNT-1).
5. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss — Sodhi M et al., JAMA 2023;330(18):1795–1797.
6. OZEMPIC (semaglutide) injection — Highlights of Prescribing Information — US Food and Drug Administration, 2025.
7. Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1 — Diabetes, American Diabetes Association.